X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215834
https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-greater-difference-of-approximately-5x-for-iomab-b-vs-control-arm-in-the-number-of-patients-potentially-evaluable-for-the-primary-endpoint-of-the-pivotal-phase-3-sierra-trial-at-the-63rd-as-301442794.html
https://globalgenes.org/2021/08/19/nice-recommends-first-treatment-for-rare-blood-disorder/
https://www.nice.org.uk/news/article/nice-recommends-first-treatment-for-rare-blood-disorder
https://www.fiercepharma.com/marketing/blueprint-challenges-novartis-new-ayvakit-nod-blood-disorders-more-competition-to-follow
https://endpts.com/astellas-aml-drug-wins-over-chmp-strengthening-lead-on-daiichi-sankyo/
https://www.raps.org/news-and-articles/news-articles/2018/9/fda-issues-54-new-and-revised-product-specific-gui?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2013%20September
https://endpts.com/as-nda-talks-loom-fda-hands-daiichi-sankyo-a-breakthrough-on-its-410m-aml-drug-quizartinib/
https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia
https://www.fiercebiotech.com/biotech/daiichi-sankyo-pursuit-novartis-rydapt-next-gen-flt3-drug?utm_source=internal&utm_medium=rss
http://www.pharmatimes.com/news/nice_oks_three_new_therapies_for_blood_cancer_1234654
http://www.pharmatimes.com/news/nice_says_no_to_novartis_aml_drug_rydapt_1213332
https://www.fiercepharma.com/pharma/nice-issues-early-no-votes-roche-s-roactemra-novartis-rydapt
Market Place
Share 
